Ceralasertib
- Generic Name
- Ceralasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24N6O2S
- CAS Number
- 1352226-88-0
- Unique Ingredient Identifier
- 85RE35306Z
- Background
Ceralasertib is under investigation in clinical trial NCT03682289 (Phase II Trial of AZD6738 Alone and in Combination With Olaparib).
- Associated Conditions
- -
- Associated Therapies
- -
Eyeing the Future of Oncology Highlights From the Presidential Symposium at ESMO Congress 2024
ESMO Congress 2024 showcased PIONeeR trial addressing PD-1/PD-L1 resistance in NSCLC, Rome trial's genomic-guided therapy improving outcomes in metastatic solid tumors, and Prov-GigaPath AI model for cancer mutation prediction and tumor microenvironment analysis.
Using Sarcoma Organoids for Drug Screening May Reveal Personalized Treatments
UCLA researchers developed a method to generate sarcoma organoids within a week post-surgery/biopsy for drug screening, identifying personalized treatments for 58% of patients. The study, published in *Cell Stem Cell*, screened 194 tumor samples from 126 sarcoma patients, revealing significant drug responses in 80.4% of cases. A clinical trial (NCT06064682) is underway to validate the assay's predictive power for osteosarcoma treatment.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath